T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 (2021)
Sequence: T7: HAIYPRH; SHRss: Stearyl-HHHCRRRRRC (disulfide-crosslinked)
| Experiment Id | EXP000238 |
|---|---|
| Paper | T7-Functionalized Cationic Peptide as a Nanovehicle for Co-delivering Paclitaxel and siR-MeCP2 |
| Peptide | T7-PEG-SHRss |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | high |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | |
| Peptide Concentration | 2 mg siRNA/kg; PTX 10 mg/kg |
| Rna Concentration | 2 mg/kg |
| Mixing Ratio | N/P = 10 |
| Formulation Format | targeted peptide nanoparticle (CTNP) |
| Formulation Components | T7-PEG-SHRss + siRNA + paclitaxel |
| Size Nm | 140.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | LNCaP and PC3 xenograft mouse models |
| Administration Route | intravenous |
| Output Type | tumor growth suppression |
| Output Value | Significant tumor volume and weight reduction; enhanced survival |
| Output Units | |
| Output Notes | Dual-targeting ADPC/AIPC; synergistic siRNA + PTX effect |
| Toxicity Notes | No cardiotoxicity; well tolerated |
| Curation Notes |